|
Oct 17
|
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
|
|
Oct 17
|
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
|
|
Oct 4
|
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
|
|
Jul 16
|
Loss-Making Ardelyx, Inc. (NASDAQ:ARDX) Expected To Breakeven In The Medium-Term
|
|
Jul 13
|
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
|
|
Apr 26
|
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
|